IBM (IBM) and IonQ (IONQ) both give investors exposure to quantum computing, but they are not the same kind of bet. IBM is the larger, more diversified “quantum infrastructure” play, with a real enterprise business behind it. IonQ is the more direct pure-play, which means it could have more upside if quantum adoption accelerates, but it also carries more valuation and execution risk. As a result, analysts currently prefer IBM stock.
Memorial Day Sale – Claim 70% Off TipRanks
IBX: an alternative to margin or options on IBMIBM Is the Safer Quantum Infrastructure Play
IBM’s biggest recent quantum catalyst is the proposed $1 billion CHIPS award it received from the U.S. Department of Commerce to support America’s first purpose-built quantum foundry. IBM also plans to contribute another $1 billion of its own capital into Anderon, a standalone quantum wafer foundry based in Albany, New York. Importantly, IBM is not just trying to build quantum computers but also build the manufacturing layer behind quantum computing, which could make it a more important long-term infrastructure player if the industry scales.
However, analysts have become increasingly positive on IBM because the company is also benefiting from AI and growing software demand. Interestingly, the fact that IBM is not a pure-play quantum computing play is both a key advantage and a limitation. IBM gives investors quantum exposure with less downside if quantum takes longer to commercialize, but quantum alone will probably not drive the stock the way it could for a smaller pure-play. Nevertheless, analysts have a Moderate Buy consensus rating on IBM stock, with an average price target of $287.80 per share, which implies 9% upside potential.
IonQ: The High Risk, High Reward Pure Quantum Bet
In contrast, IonQ is the cleaner bet for investors who want direct exposure to quantum computing. Unlike IBM, IonQ does not have a massive legacy business, so the stock is much more tied to investor confidence in quantum commercialization. At the same time, analyst commentary has been positive, with five-star Wedbush analyst Antoine Legault raising the firm’s price target to $75 from $60 while keeping a Buy rating. Separately, Northland’s five-star-rated Nehal Chokshi initiated coverage on IonQ with an Outperform rating, calling it a best-in-class quantum name.
The risk, though, is that IonQ already trades like a company that is expected to win big. IonQ is also an early-stage company that is unprofitable, so investors have to be comfortable with volatility, losses, and a long commercialization timeline. The bull case is that IonQ’s trapped-ion technology and partnerships could make it one of the main winners if quantum computing becomes commercially useful sooner than expected. The bear case is that the stock may have already priced too much of that future.
As a result, although analysts have a Strong Buy consensus rating, the average IONQ price target of $62.79 per share implies 10.5% downside risk.
